| A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses JM Steichen, YC Lin, C Havenar-Daughton, S Pecetta, G Ozorowski, ... Science 366 (6470), eaax4380, 2019 | 176 | 2019 |
| HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage E Landais, B Murrell, B Briney, S Murrell, K Rantalainen, ZT Berndsen, ... Immunity 47 (5), 990-1003. e9, 2017 | 95 | 2017 |
| Rapid and focused maturation of a VRC01-class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-glycan J Umotoy, BS Bagaya, C Joyce, T Schiffner, S Menis, KL Saye-Francisco, ... Immunity 51 (1), 141-154. e6, 2019 | 67 | 2019 |
| Co-evolution of HIV envelope and apex-targeting neutralizing antibody lineage provides benchmarks for vaccine design K Rantalainen, ZT Berndsen, S Murrell, L Cao, O Omorodion, JL Torres, ... Cell reports 23 (11), 3249-3261, 2018 | 51 | 2018 |
| Nitrosopurines en route to potently cytotoxic asmarines KK Wan, K Iwasaki, JC Umotoy, DW Wolan, RA Shenvi Angewandte Chemie 127 (8), 2440-2445, 2015 | 37 | 2015 |
| Synthesis and Sulfur Electrophilicity of the Nuphar Thiaspirane Pharmacophore N Tada, DJ Jansen, MP Mower, MM Blewett, JC Umotoy, BF Cravatt, ... ACS central science 2 (6), 401-408, 2016 | 25 | 2016 |
| Selective inhibition of initiator versus executioner caspases using small peptides containing unnatural amino acids CJ Vickers, GE González-Páez, KM Litwin, JC Umotoy, EA Coutsias, ... ACS Chemical Biology 9 (10), 2194-2198, 2014 | 21 | 2014 |
| Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection PJM Brouwer, A Antanasijevic, AJ Ronk, H Müller-Kräuter, Y Watanabe, ... Cell Host & Microbe 30 (12), 1759-1772. e12, 2022 | 20 | 2022 |
| Small‐Molecule Procaspase Activators Identified Using Fluorescence Polarization CJ Vickers, GE González‐Páez, JC Umotoy, C Cayanan‐Garrett, ... ChemBioChem 14 (12), 1419-1422, 2013 | 19 | 2013 |
| Antibody conjugates for targeted therapy against HIV-1 as an emerging tool for HIV-1 cure JC Umotoy, SW De Taeye Frontiers in immunology 12, 708806, 2021 | 15 | 2021 |
| A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science 366: eaax4380 JM Steichen, YC Lin, C Havenar-Daughton, S Pecetta, G Ozorowski, ... | 10 | 2019 |
| Co-evolution of HIV envelope and apex-targeting neutralizing antibody lineage provides benchmarks for vaccine design. Cell Rep 23: 3249–3261 K Rantalainen, ZT Berndsen, S Murrell, L Cao, O Omorodion, JL Torres, ... | 6 | 2018 |
| Evolution of a Chemical Strategy Toward the Synthesis of Unsymmetrically Oxidized Nuphar Alkaloids JJ Lacharity, A Zakarian Synlett 30 (14), 1632-1642, 2019 | 1 | 2019 |
| Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer J van Schooten, A Schorcht, E Farokhi, JC Umotoy, H Gao, ... PLoS pathogens 18 (11), e1010945, 2022 | | 2022 |
| PP 8.8–00129 Antibody mediated killing of HIV-1 infected cells with glycoengineered broadly neutralizing antibodies S De Taeye, A Schriek, J Umotoy, M Grobben, D Falck, R Sanders, ... | | 2022 |
| Engineering better bnAbs PN Kelly Science 366 (6470), 1209-1211, 2019 | | 2019 |
